Project Grant HT94252510608
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$327K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This federal Project Grant award of $749,996.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The research aims to uncover therapeutic vulnerabilities and deliver new treatments to improve clinical outcomes for lethal prostate cancer. The grant funds a 4-year research initiative from August 1, 2025 to July 31, 2029 to advance the...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation focused on "Targeting MNK/GRP78 Pathway to Disrupt Proteostasis Rewiring in Castration-Resistant Prostate Cancer". The $1,602,137 award, spanning from April 2025 to April 2028, aims to investigate innovative medical solutions for military personnel and the broader...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
This $481,056.00 Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research at the University of California, Davis focused on investigating the role of the ARHGEF2 gene in prostate cancer treatment resistance and neural lineage plasticity. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing the understanding of prostate...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
The Department of Defense's Defense Health Agency awarded a $241,500 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports research to understand the molecular communication between different types of prostate cancer cells. This fundamental research, to be conducted at Duke University in Durham, North Carolina, aims to transform healthcare for military service members, veterans, and the...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The federal Project Grant award of $1,477,615.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. This research, conducted by the University of British Columbia, aims to transform healthcare for military service members, veterans, and the broader public through innovative and...